Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Subscribe To Our Newsletter & Stay Updated
